DLL3×CD3 bispecific T-cell engager antibody immunotherapy (also known as obrixtamig) that binds DLL3 on tumor cells and CD3 on T cells to activate cytotoxic T-cell killing.
A DLL3xCD3 bispecific T-cell engager antibody that binds DLL3 on tumor cells and CD3 on T cells, activating and redirecting cytotoxic T cells to form immune synapses and kill DLL3-expressing cancer cells.
NO
INDIRECT
The bispecific antibody binds CD3ε on T cells and DLL3 on tumor cells, activating T cells to kill DLL3-expressing tumor cells via immune synapse and perforin–granzyme release; CD3ε+ T cells are not targeted for killing.
Autologous BCMA-directed CAR T-cell therapy in which a patient's T cells are engineered ex vivo to express a CAR recognizing BCMA on malignant plasma cells, triggering cytokine release and cytolytic killing in multiple myeloma.
Autologous T cells are genetically modified ex vivo to express a chimeric antigen receptor targeting BCMA on malignant plasma cells; CAR engagement triggers T-cell activation, cytokine release, proliferation, and perforin/granzyme-mediated cytolytic killing of BCMA-positive cells in multiple myeloma.
YES
DIRECT
BCMA-specific CAR T cells recognize BCMA on target cells and, upon activation, kill them via perforin/granzyme-mediated cytolysis (apoptosis).
Autologous CD19-directed CAR T-cell therapy in which a patient's T cells are engineered ex vivo to express a CAR recognizing CD19 on malignant B cells, inducing T-cell effector functions and cytotoxicity in NHL/CLL.
Autologous T cells engineered ex vivo to express a CD19-specific chimeric antigen receptor; upon binding CD19 on malignant B cells, the CAR activates T-cell effector functions (cytokine release and perforin/granzyme-mediated cytotoxicity) to eliminate CD19+ cells.
YES
DIRECT
CD19-directed CAR T cells bind CD19 on target cells, triggering T-cell activation and killing via perforin/granzyme-mediated cytolysis and Fas–FasL–mediated apoptosis.
Subcutaneous bispecific T‑cell–engaging antibody (CD3×CD20) that redirects cytotoxic T cells to kill CD20+ B cells.
Bispecific monoclonal antibody that simultaneously binds CD3 on T cells and CD20 on B cells, crosslinking T cells to CD20+ malignant B cells to trigger T‑cell activation and cytotoxic killing (immune synapse formation, perforin/granzyme release, cytokine production) of the target B cells.
YES
DIRECT
CD3×CD20 bispecific antibody crosslinks T cells to CD20+ cells, forming an immune synapse and inducing T-cell cytotoxicity via perforin/granzyme (and death receptor) pathways, killing the CD20-expressing cells.
Rabbit polyclonal antilymphocyte globulin used for in vivo T-cell depletion to reduce graft-versus-host disease risk.
Rabbit polyclonal IgG against multiple human T‑cell surface antigens (e.g., CD2, CD3, CD4, CD8, HLA) that depletes T lymphocytes via complement-dependent cytotoxicity, Fc-mediated ADCC/phagocytosis, and apoptosis, producing in vivo T‑cell immunosuppression to reduce GVHD risk.
YES
DIRECT
rATG contains antibodies to CD3 that bind CD3E on T cells and deplete them via complement-dependent cytotoxicity and Fc-mediated effector functions (ADCC/phagocytosis), with additional apoptosis upon cross-linking.